Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

Fig. 8

ARV-825 shows cytotoxicity in primary T-ALL cells. a Growth of primary T-ALL cells treatment with 1 μM ARV-825 (Case 1); ARV-825 suppressed BET and c-Myc protein expression in primary T-ALL cells from various concentration of ARV-825. b 8 μM ARV-825 treatment impaired growth of pediatric primary T-ALL cells (Case 2). ARV-825 suppressed BET and c-Myc protein expression in primary T-ALL cells from various concentration of ARV-825

Back to article page